Has the battle against antipsychotic weight gain been won? :

Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).

Related Keywords

Virginia , United States , Eric Keller , Paul Sweetnam , Joseph Coyle , Response Pharmaceuticals , Harvard Medical School , Clinical Development , Markets Amp Regulations , Atient Centricity , Linical Evolution , Pis Active Pharmaceutical Ingredients , Hasei Ii , Weight Loss , Small Molecule Drugs , Obesity , Antipsychotic ,